Pharmaceutical company Biontech expects mRNA cancer therapy to be approved in 2030. The founder of the company said that the technology on which the company’s corona vaccine is based can also be used against autoimmune diseases.
Biontech founder Özlem Türeci (54) told the Funke newspapers media group, “The principle of mRNA vaccination in cancer is that the immune system presents the tumor’s recognition features – demanding that it attack cells with this feature.” Thursday.
But with mRNA, the opposite is also possible: teaching the immune system not to attack cells with certain recognition properties. This can help with autoimmune diseases where your own healthy cells are seen as foreign and attacked. “We’ve already shown in preclinical studies that this works,” Türeci added. As a result, however, advances in cancer took significantly longer than in the field of infection.
Moderna reaches milestone in cancer vaccine
Moderna also reached a milestone in cancer treatment this week. Moderna chief physician Paul Burton (54) even talks about a revolution. Moderna, the world’s first pharmaceutical company, has completed phase 2 study of an innovative mRNA cancer vaccine with promising results.
According to Moderna, skin cancer patients who received the mRNA cancer vaccine had a significantly lower risk of dying from the cancer or getting the disease again at a later date. Cancer vaccines may be on the market in just a few years. (SDA/kae)